THE European Medicines Agency
has recommended approval of
Revestive (teduglutide) for the
treatment of adult patients with
short bowel syndrome.
Revestive is the first medical
treatment recommended for
approval in Europe for short bowel
syndrome (a condition in which
nutrients are not properly
absorbed, due to severe intestinal
disease or the surgical removal of a
large portion of the small
intestine).The above article was sent to subscribers in Pharmacy Daily's issue from 25 Jun 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Jun 12
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.